Celcuity’s newly launched REVTORPYK combines strong clinical differentiation and a $754M runway with meaningful execution, tolerability, and convertible-debt risks.
Overview
Celcuity has moved from clinical-stage biotechnology into commercial oncology after FDA approval of REVTORPYK (gedatolisib) on July 14, 2026; U.S. sales began September 30. Its lead asset is a weekly IV pan-PI3K/mTORC1/2 inhibitor for HR+/HER2- advanced breast cancer, supported by a live-cell functional diagnostic platform. REVTORPYK is differentiated in PIK3CA wild-type disease, where its triplet cut progression-or-death risk by 76% versus fulvestrant control and it is the only targeted PAM therapy approved for the segment. It also demonstrated mPFS of 11.1 versus 5.6 months against alpelisib in mutated disease; an sNDA was filed in August 2026. **The central opportunity is to scale an approved, guideline-preferred therapy into a large underserved market, then expand through the mutant label and first-line VIKTORIA-2.** Q2 2026 revenue was $0 before launch, while net loss widened to $82.27M and SG&A rose to $35.04M to build commercial capacity. Liquidity was $754.04M, projected to fund launch and trials into 2028, though convertible notes carry $753.24M principal. At $55.61 in mid-October, the report’s probability-weighted five-year target is $93.89; near-term catalysts are Q4 2026/Q1 2027 sales evidence, a mid-2027 sNDA decision, and VIKTORIA-2 data in 2027/2028.